# Nuclide record precirix (company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/companies/precirix/>
  a schema:Organization ;
  nuclide:kind "company" ;
  schema:identifier "precirix" ;
  schema:name "Precirix"@en ;
  schema:description "Precirix, of Brussels, develops radiopharmaceuticals built on small single-domain antibody fragments that carry a radioactive isotope to HER2-positive cancers. Its lead, CAM-H2, is in a phase 1/2 trial in HER2-positive breast, gastric and gastro-oesophageal cancer, including patients with brain metastases, with an imaging dose given first to confirm HER2 in the lesions."@en ;
  schema:url <https://nuclide.cc/companies/precirix/>, <https://www.evergreentgn.com/2023/06/08/cam-h2-production-at-evergreen-marks-the-expansion-of-precirix-clinical-trial-to-the-us/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.evergreentgn.com/2023/06/08/cam-h2-production-at-evergreen-marks-the-expansion-of-precirix-clinical-trial-to-the-us/> ;
  schema:addressCountry "BE" ;
  nuclide:indications <https://nuclide.cc/indications/breast-her2-positive/> ;
  nuclide:technologies <https://nuclide.cc/technologies/radioligand-therapy/> ;
  nuclide:targets <https://nuclide.cc/targets/her2/> .